Tekla Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Tekla Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.83M	Hold	422,281	–	–	0.11%	102
2023 Q1	$3.73M	Hold	422,281	–	–	0.14%	87
2022 Q4	$3.23M	Hold	422,281	–	–	0.12%	94
2022 Q3	$3.01M	Buy	422,281 +84,559	+25%	+$796K	0.12%	98
2022 Q2	$2.73M	Hold	337,722	–	–	0.11%	106
2022 Q1	$4.69M	Hold	337,722	–	–	0.16%	98
2021 Q4	$9.48M	Hold	337,722	–	–	0.3%	72
2021 Q3	$11.5M	Hold	337,722	–	–	0.37%	67
2021 Q2	$13.8M	Hold	337,722	–	–	0.45%	53
2021 Q1	$13.6M	Buy	337,722 +51,709	+18%	+$2.8M	0.47%	58
2020 Q4	$16.9M	Buy	286,013 +261,298	+1,057%	+$13.5M	0.59%	49
2020 Q3	$1.2M	Buy	+24,715	New	+$1.04M	0.05%	174

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Tekla Capital Management's ADPT Position: Q2 2023 in Review

Tekla Capital Management held its Adaptive Biotechnologies (ADPT) position steady in Q2 2023 at 422,281 shares worth $2.83M. The position accounts for 0.11% of the portfolio, ranked #102.

Tekla Capital Management first reported a position in ADPT in Q3 2020 and has held it in 12 quarters since. The position peaked at $16.9M in Q4 2020. 210 funds tracked by Wall St. Rank hold ADPT as of Q2 2023.

Tekla Capital Management held 422,281 shares of Adaptive Biotechnologies worth $2.83M as of Q2 2023.
Tekla Capital Management left its Adaptive Biotechnologies share count unchanged in Q2 2023.
Adaptive Biotechnologies made up 0.11% of Tekla Capital Management's portfolio in Q2 2023, its #102 holding.
Tekla Capital Management first reported a position in Adaptive Biotechnologies in Q3 2020 and has held it in 12 quarters since.
Tekla Capital Management's Adaptive Biotechnologies position peaked at $16.9M in Q4 2020.
210 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.